Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 18.71 · gapped below the open, then crossed back over prior close. High/low 18.73 at 1:00 pm ET, 18.67 at 9:30 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Takeda paid us a $40.0 million upfront payment related to the collaboration, and an additional $110.0 million under a share purchase agreement in February 2018.”
FILING10-K0001714899-25-000066cik 0001714899disclosed by DNLI
“To Ipsen, we granted the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted such rights in Japan.”
FILING10-K0000939767-26-000021cik 0000939767disclosed by EXEL
“Under the Amended Takeda CLA, Takeda will continue to purchase our Matrix-M™ adjuvant to manufacture doses of finished COVID-19 Vaccine with updated adjuvant forecast and other supply terms.”
FILING10-K0001000694-26-000007cik 0001000694disclosed by NVAX
“For example, we co-developed soticlestat with Takeda Company Limited ("Takeda") through completion of Phase 2 clinical trials and subsequently sold our rights back to Takeda under a royalty, license and termination agreement ("RLT Agreement").”
FILING10-K0001628280-26-019438cik 0001636651disclosed by OVID
“Osavampator was in-licensed from Takeda Pharmaceutical Company Limited (Takeda) in 2020, and we have exclusive worldwide rights to develop and commercialize osavampator, except in Japan, where Takeda has exclusive development and commercialization rights.”
FILING10-K0000914475-26-000007cik 0000914475disclosed by NBIX
“In September 2022, we entered into an exclusive license agreement with Takeda to license the worldwide research and development and commercial rights to alisertib.”
FILING10-K0001437749-26-005891cik 0001401667disclosed by PBYI
“In addition, we are obligated to pay Takeda low-to-mid single-digit royalties based on net sales of products containing the licensed compounds by us, our affiliates or sublicensees, subject to specified reductions.”
FILING10-K0001601830-26-000039cik 0001601830disclosed by RXRX
“License and collaboration agreement with Takeda Pharmaceuticals On January 23, 2023 (as amended in June 2025), the Group and Takeda Pharmaceuticals International AG ( " Takeda " ) entered into an exclusive out-licensing agreement (the " Takeda Agreement " ) in territories outside of Mainland China, Hong Kong and Macau (the " Territory " ) to further the global development, commercialization and manufacturing of Fruzaqla, also known as fruquintinib, a targeted oncology therapy for the treatment of various types of solid tumors.”
FILING20-F0001104659-26-023822cik 0001648257disclosed by HCM
“In December 2024, Takeda entered into an exclusive licensing agreement with Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.”
FILING20-F0001395064-26-000177cik 0001395064
“In January 2024, Takeda signed a worldwide license and collaboration agreement with Protagonist for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV).”
FILING20-F0001395064-26-000177cik 0001395064
“In December 2017, we entered into a Patent License Agreement with TiGenix, now a wholly owned subsidiary of Takeda, which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived MSC product Alofisel ® , previously known as Cx601, a product candidate of Takeda, for the local treatment of fistulae.”
FILING20-F0001345099-25-000067cik 0001345099disclosed by MESO
“We are party to a license agreement with Takeda that was originally entered into in March 2019, or the Takeda License Agreement, between Takeda and Petra Pharma Corporation, or Petra, which was subsequently assigned by Petra to Ravenna Pharmaceuticals, Inc., or Ravenna, and later acquired by Faeth in February 2021 in connection with its acquisition of assets related to serabelisib pursuant to an asset purchase agreement with Ravenna.”
FILING10-K0001193125-26-132014cik 0001829802disclosed by FTH
“On April 3, 2023, the Company announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.”
FILING20-F0001598599-26-000005cik 0001598599disclosed by IPHA
“In May 2024, Takeda entered into an exclusive, worldwide option and license agreement with AC Immune for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer”
FILING20-F0001395064-26-000177cik 0001395064
“In February 2018, Takeda entered into an agreement with Wave to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system (CNS).”
FILING20-F0001395064-26-000177cik 0001395064
“In October 2025, Takeda entered into a license and collaboration agreement with Innovent for the development, manufacturing and commercialization of two late-stage investigational medicines for solid tumors, IBI363 and IBI343, worldwide outside of China, Hong Kong, Macau and Taiwan.”
FILING20-F0001395064-26-000177cik 0001395064
“In March 2025, Takeda entered into a development funding agreement with BXLS for mezagitamab (TAK-079).”
FILING20-F0001395064-26-000177cik 0001395064
Watchlist prices, news filtered to it, and its next report on your desk.
Takeda Pharmaceutical Co Ltd
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Takeda Pharmaceutical Co Ltd has 12 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Takeda Pharmaceutical Co Ltd’s own annual report or the counterparty’s, and carries the sentence that discloses it.
TAK (Takeda Pharmaceutical Co Ltd) has 12 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: FTH −8.21%, in healthcare.